Edit
Black Diamond Therapeutics
https://bdtherapeutics.com/Last activity: 06.07.2021
Probably Closed - Reference to Black Diamonds Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS and BRAF alterations in NSCLC and other solid tumors.
Location: United States
Employees: 51-200
Total raised: $170M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.12.2019 | Series C | $85M | - |
| 10.01.2019 | Series B | $85M | New Enterp... |
Mentions in press and media 3
| Date | Title | Description |
| 05.12.2019 | Black Diamond Therapeutics Raises $85M in Series C Financing | Black Diamond Therapeutics, Inc., a Cambridge, Mass.-based precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, completed a Series C financing of $85m. The round was led b... |
| 10.01.2019 | NEA Co-Leads $85M Series B in Black Diamond Therapeutics | Black Diamond Therapeutics, Inc., a biotechnology company developing next-generation precision medicines for cancer, today announced the completion of an oversubscribed Series B financing of $85 million co-led by New Enterprise Associates a... |
| 10.01.2019 | Black Diamond Therapeutics Closes $85M Series B Financing | Black Diamond Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company developing next-generation precision medicines for cancer, completed an $85m Series B financing. The round was co-led by New Enterprise Associates and RA Capit... |